Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers. - Wikidata - wikimedia - TriplyDB

Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers.

Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers.

http://www.wikidata.org/entity/Q37269571

about

Clinical and metabolic parameters in non-small cell lung carcinoma and colorectal cancer patients with and without KRAS mutations.Mini profile of potential anticancer properties of propofol.Inhibition of lung adenocarcinoma cells by insulin-like growth factor-I receptor and Kirsten rat sarcoma mutations: A mutation analysis with antisense oligodeoxynucleotide.Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia.Frequency and Spectrum of KRAS Mutations in Moroccan Patients with Lung Adenocarcinoma.Variation in KRAS driver substitution distributions between tumor types is determined by both mutation and natural selection.Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients.

P2860

Q34347975-3ADCD992-010E-4738-841A-E500208C04EF Q35515984-3E14601B-CA78-4933-8411-7DED0AF8F0B0 Q35663425-02124627-43D2-460C-9114-F7E6C2462B43 Q37272817-860C2B06-30CB-42A7-8B46-11621844273E Q37651033-F9180CA2-33C8-480E-BE91-04F04FC55933 Q38594037-3D71AD54-07DC-408F-A105-E25A27A3DD86 Q52332839-290DB9CB-78B6-464D-8A87-F73F012ADD46

P2860

Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers.

http://www.wikidata.org/entity/Q37269571

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 29 August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Differences in EGFR and KRAS m ...... ma of never and heavy smokers.

@en

Differences in EGFR and KRAS m ...... ma of never and heavy smokers.

@nl

type

label

Differences in EGFR and KRAS m ...... ma of never and heavy smokers.

@en

Differences in EGFR and KRAS m ...... ma of never and heavy smokers.

@nl

prefLabel

Differences in EGFR and KRAS m ...... ma of never and heavy smokers.

@en

Differences in EGFR and KRAS m ...... ma of never and heavy smokers.

@nl

P1433

Q37269571-5420335D-6928-4F91-9774-473C22FA0517

P1476

Q37269571-759A1029-26AB-4A94-A75A-2D754FAEC463

P2093

Q37269571-0FFCFFD3-0223-4F90-A022-28F4F264E7FE

Q37269571-9983E98C-5831-4E2A-9EEA-468DB203D6FF

Q37269571-EC85344C-2B39-4A4F-9D33-F05A8E537277

P2860

Q37269571-084877BB-228C-44CB-A5C7-F9349F0DA083

Q37269571-150F8ADD-F479-4EC5-BF41-18FF9F428DFC

Q37269571-1D0107CF-6B73-4DFD-AEB7-EED2CCCAF6C2

Q37269571-20C04B9C-E157-4CDD-B72E-A6543122B93B

Q37269571-2B7056B1-0D1E-4189-9B5C-C952C64F229E

Q37269571-2CBD13B4-C12C-4F3E-834F-9BF07CDEBE25

Q37269571-45A0D752-251E-40EF-AE7B-501E51F0CF7A

Q37269571-4B22E629-904E-4CBC-8A90-512BD9FD5ABB

Q37269571-4F861D2D-D2E2-4ACB-A277-41B4E0B39C54

Q37269571-559682C2-E3DE-4742-A402-27BF4AB412D5

P304

Q37269571-D37F1B42-539C-403C-B13D-38772EB322D3

P31

Q37269571-E7E924B5-E39A-4EFC-A20E-CACA71C9B38F

P356

Q37269571-EACF33BB-E92A-4DA3-8E5B-10D616301D5B

P433

Q37269571-85F1A8C9-37A4-462C-A5AA-3DBC836341DA

P478

Q37269571-0829051D-DB3D-4AF4-97B6-701EEFF74DC8

P577

Q37269571-AB5EBEF3-F7CC-4E0A-B23F-227DB437747E

P5875

Q37269571-D3983042-3252-4769-B788-ECD559FC7834

P698

Q37269571-EFC3194C-DD66-4AEC-A82C-45CFEE089F1E

P921

Q37269571-DFF7DAB6-8207-4EB5-9D16-077F14E7BBAA

P932

Q37269571-C3EC02BD-BBB4-46C9-BCEE-6F9147783B93

P356

P1433

Oncology Letters

P1476

Differences in EGFR and KRAS m ...... ma of never and heavy smokers.

@en

P2093

Kazuya Takamochi

http://www.w3.org/2001/XMLSchema#string

Kenji Suzuki

http://www.w3.org/2001/XMLSchema#string

Shiaki Oh

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

ras oncogenes in human cancer: a review

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer.

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

P304

1207-1212

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2013.1551

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258216327

http://www.w3.org/2001/XMLSchema#string

P698

24179496

http://www.w3.org/2001/XMLSchema#string

P921

P932

3813793

http://www.w3.org/2001/XMLSchema#string